NCT06659445View on ClinicalTrials.gov

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

324

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions
Geographic Atrophy (GA)Age - Related Macular Degeneration (AMD)
Interventions
DRUG

ONL1204 Opthalmic solution

Liquid formulation ONL1204 Ophthalmic Solution administered by intravitreal (IVT) injection

DRUG

Avacincaptad Pegol intravitreal solution

Liquid formulation Avacincaptad Pegol administered by intravitreal (IVT) injection

OTHER

Sham

Sham injection

Sponsors

Lead Sponsor

ONL Therapeutics
All Listed Sponsors
lead

ONL Therapeutics

INDUSTRY

NCT06659445 - Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD | Biotech Hunter | Biotech Hunter